Yes, many people with spina bifida walk, and the ability to walk depends almost entirely on the level of the spinal lesion and the type of spina bifida involved. Children with the mildest form, spina bifida occulta, typically walk without difficulty. Those with myelomeningocele, the most severe form, often walk with braces or assistive devices, and some use wheelchairs for long distances or full-time mobility.
The mechanics of walking with a spinal lesion
Spina bifida disrupts the neural tube, the structure that folds into the brain and spinal cord during the first 28 days of pregnancy. In myelomeningocele, the spinal cord and meninges protrude through an opening in the vertebrae and are exposed at birth. The nerves below that opening either fail to form properly or are damaged, which means the muscles they supply receive weak or absent signals.
Walking is a chain of controlled commands: the brain sends signals down the corticospinal tract, spinal circuits coordinate alternating flexor and extensor bursts, and sensory feedback from the feet and joints adjusts each step. When the lesion interrupts these pathways, three things happen downstream. Muscles below the lesion weaken or paralyze. Sensation in the feet and legs diminishes, so balance and position sense degrade. And the ankles, knees, and hips lose the stabilizing tone that keeps the body upright against gravity.
The result is a gait that demands far more energy than typical walking. Hip flexors and knee extensors must be recruited consciously rather than automatically. Ankle push-off, which normally provides much of forward propulsion, disappears when calf muscles are denervated. The person compensates with hip hiking, circumduction, or trunk leaning, and each compensation raises oxygen cost.
The lesion level is the single strongest predictor of walking ability because it maps to which muscle groups retain nerve supply. Lumbar and sacral segments control the hip, knee, and ankle muscles in sequence from top to bottom. A lesion at S1 spares most of the hip and knee musculature but weakens the calf. A lesion at L3 spares hip flexors and some knee extensors but removes ankle control. A thoracic lesion removes everything below the trunk.
Quantified context by lesion level
The classic functional classification ties walking outcomes to the highest intact vertebral level. Thoracic lesions, roughly T12 and above, leave the lower limbs without volitional control in most cases; about 90 percent of children with thoracic-level myelomeningocele use wheelchairs for community mobility by school age. Lumbar lesions at L1 to L2 often preserve hip flexion but not knee extension, and ambulation with braces is possible in a minority. Lesions at L3 to L4 preserve hip flexors and quadriceps partially, and roughly half of these children walk with bracing. Lesions at L5 and below, and sacral lesions, preserve hip and knee function with variable ankle control, and the majority walk independently or with ankle-foot orthoses.
A commonly cited benchmark: approximately 20 to 25 percent of children with myelomeningocele walk without any device, about 40 to 50 percent walk with braces or assistive devices, and the remainder rely on wheelchairs for most mobility. These figures shift with age and with the era of surgical management, but the lesion-level gradient holds across cohorts.
Energy cost matters as much as the ability to take steps. Children with myelomeningocele who ambulate typically expend 30 to 50 percent more energy per meter walked than typically developing peers, and the gap widens at higher lesion levels. That metabolic tax is why many ambulators transition to wheelchair use during adolescence, when body mass rises and the upper limbs become more efficient for long-distance travel.
Ambulation outcomes across the lifespan
Walking status in spina bifida is not fixed at birth. It follows a developmental arc, with gains in childhood and often losses in adolescence and adulthood. The timeline below reflects typical patterns reported in longitudinal clinic cohorts.
| Age range | Typical mobility pattern | Key driver |
|---|---|---|
| Birth to 1 year | No ambulation; motor milestones delayed | Neural tube defect repair and hydrocephalus management |
| 1 to 3 years | Pull to stand and first steps with bracing in lower lesions | Orthotic fitting and therapy intensity |
| 3 to 6 years | Independent or device-assisted walking in lumbar and sacral lesions | Muscle strength and balance training |
| 6 to 12 years | Peak ambulation rates; many thoracic-level children remain wheelchair users | School participation and endurance demands |
| 12 to 18 years | Some ambulators transition to wheelchair for community distances | Growth, weight gain, and energy cost |
| Adulthood | Ambulation rates decline; wheelchair use rises | Joint wear, obesity, pain, and skin integrity |
The adolescent decline is well documented and often surprises families who expected steady progress. It is driven less by motivation than by biomechanics: a longer limb with the same weak musculature requires proportionally more force, and the energy penalty compounds.
Spina bifida occulta and other mild presentations
Spina bifida occulta is the mildest form and involves a hidden defect in the posterior vertebral arch without herniation of the cord or meninges. Most people with occulta never know they have it, and it is often found incidentally on imaging. Walking is normal in the overwhelming majority. A small subset develops tethered cord syndrome, in which the spinal cord adheres to surrounding tissue and stretches with growth, producing leg weakness, gait changes, or bladder dysfunction. In that subset, walking can deteriorate, and surgical release of the tether may restore or preserve function.
Meningocele, in which meninges protrude but the cord does not, generally produces milder deficits than myelomeningocele, and most children with meningocele walk. The distinction matters because families often hear "spina bifida" as a single diagnosis when the spectrum runs from an incidental radiographic finding to severe lifelong disability.
Common misconceptions and a professional caveat
A persistent misconception is that walking ability is determined at birth and cannot change. In reality, ambulation is modifiable through orthotics, therapy, and surgical correction of deformities. Another is that braces weaken muscles; appropriately fitted orthoses support alignment and can preserve function rather than replace it. A third is that wheelchair use represents failure. For many people with spina bifida, a wheelchair is a tool for participation, not a sign of decline, and mixing ambulation at home with wheelchair use in the community is a common and effective strategy.
Here is the counterintuitive clinical caveat: preserved walking ability does not always mean preserved joint health. Ambulators with myelomeningocele face elevated rates of hip and knee osteoarthritis, pressure injuries from orthoses, and falls, and some clinicians counsel patients to consider wheelchair use earlier than families expect precisely to protect joints for decades. The goal is mobility across the lifespan, not maximal step count at any single age.
Practical actions and red-flag warnings
Mobility management works best as a partnership among orthotists, physical therapists, neurosurgeons, and the person with spina bifida. Concrete steps include:
Get fitted for orthoses by a clinician experienced with pediatric or adult spina bifida, and refit whenever growth or gait changes. Schedule physical therapy focused on hip and knee strengthening, balance, and energy-efficient gait, not stretching alone. Track endurance with a simple distance or time log to catch decline early. Maintain skin checks under braces and footwear daily, since sensation is reduced. Address bowel and bladder management, because continence planning directly affects school and work participation.
Warning signs that warrant prompt clinical review:
A new or progressive loss of walking ability, especially during a growth spurt. New back pain, leg weakness, or changes in bladder function, which can signal tethered cord. A foot that suddenly turns inward or develops a new deformity. Skin breakdown or pressure sores under an orthosis. Rapid weight gain that coincides with falling endurance.
Limits of the evidence
Walking outcomes in spina bifida are drawn largely from single-center cohorts and registry data, not randomized trials, so precise percentages vary by era, surgical technique, and follow-up duration. Prenatal repair of myelomeningocele, compared with postnatal repair, improves motor outcomes in some trials, with more children able to walk independently, but the effect size depends on lesion level and on complications such as preterm birth (a major trial reported higher rates of preterm delivery after prenatal repair) (Adzick et al., New England Journal of Medicine, 2011). Hydrocephalus, present in roughly 80 percent of children with myelomeningocele, adds its own effects on cognition and motor planning that shape mobility independently of the spinal lesion.
Any statement about prognosis should be framed as a range, not a promise. The honest answer to whether someone with spina bifida can walk is: often yes, sometimes with devices, and sometimes not, with the lesion level, associated hydrocephalus, orthotic care, and lifelong monitoring all shaping the trajectory.